CD19 and liver cancer: Overall, over 60 CAR-T trials for pediatric application are currently open, recruiting or ongoing (see www.clinicaltrials.gov, accessed 21 February 2022), with targets such as acute lymphoblastic leukemia (anti-CD19, anti-CD22, anti-CD19/22, anti-CD20/19), CNS tumors and sarcomas (anti-B7H3, anti-HER2, anti-EGFR806), Hodgkin lymphoma (anti-CD30), liver cancer (anti-GAP), neuroblastoma (anti-GD2), myeloid leukemia (anti-CD33, anti-CD123) and T cell lymphoblastic leukemia (anti-CD7).